ELISpot and FluoroSpot Assay Market Forecast to Grow at CAGR of 7.2 Percent through 2031 Amid Rising Incidences of Infectious and Autoimmune Diseases

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global ELISpot and FluoroSpot Assay Market- (By Product (Assay Kits (Assay Kits by Technique(ELISpot Assay Kits, FluroSpot Assay Kits), Assay Kits by Utility (Diagnostic Kits, Research Kits), Assay Kits by Analyte (T-cell-based kits, B-cell-based kits, Other analytic kits), Analyzers, Ancillary products), By Application (Diagnostic Applications (Infectious Diseases, Transplants), Research Applications (Vaccine Development, Clinical Trials, Cancer Research)), By End-User (Hospitals & Clinical Labs, Research Institutes, Biopharmaceutical Companies and CROs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global ELISpot and FluoroSpot Assay Market is valued at US$ 276.18 Mn in 2022, and it is expected to reach US$ 512.39 Mn by 2031, with a CAGR of 7.2% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2000

The increasing prevalence of chronic conditions, including cancer and autoimmune disorders, serves as a major catalyst for the growth of the Enzyme-Linked Immunospot (ELISPOT) and Fluorospot assay market. These diagnostic platforms play a critical role in the early detection of disease, monitoring disease progression, and evaluating the effectiveness of therapeutic interventions. Despite their clinical utility, the National Cancer Institute has advised against the use of ELISPOT assays for monitoring immune responses to cancer antigens in clinical therapeutic trials, citing limitations in their application for this purpose.

Concurrently, the rising incidence of infectious diseases such as Human Immunodeficiency Virus (HIV) and tuberculosis is further driving demand for these assays. ELISPOT and Fluorospot technologies provide valuable insights into immune responses and disease-specific biomarkers, making them indispensable tools in both clinical research and healthcare settings. Their ability to deliver precise immunological data continues to support their expanding role in diagnostic and therapeutic evaluation.

List of Prominent Players in the ELISpot and FluoroSpot Assay Market:
• Oxford Immunotec (UK)
• Cellular Technology Limited (US)
• Mabtech (Sweden)
• Becton Dickinson and Company (US)
• Abcam plc. (UK)
• Bio-Techne. (US)
• Mikrogen Diagnostik (Germany)
• Autoimmun Diagnostika GmbH (Germany)
• U-CyTech (Netherlands)
• Medix Biochemica (Finland)
• Merck KGaA (Germany)
• Bio-Sys GmbH (Germany)
• Anogen-Yes Biotech Laboratories Ltd (Canada)
• Abnova Corporation (Taiwan)
• Biorbyt Ltd (UK),
• Tokyo Chemical Industry Co., Ltd. (Japan),
• MP BIOMEDICALS. (US),
• BOC Sciences. (US),
• ZenBio, Inc (US)
• Jackson ImmunoResearch Inc (US),
• Krishgen Biosystems. (India)
• NATIONAL ANALYTICAL CORPORATION (India),
• STEMCELL Technologies Inc. (Canada),
• SERVA Electrophoresis GmbH (Germany),
• IST Scitific LTD (England).

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Drivers:
Manufacturers are increasingly engaging in strategic acquisitions, partnerships, and collaborations with regional and local entities to meet the rising demand for ELISpot and FluoroSpot assay diagnostics in emerging markets. For example, in February 2022, @Siemens Healthineers (Germany) partnered with @UNICEF (United States) to enhance healthcare infrastructure in Sub-Saharan Africa by expanding access to diagnostic services and treatment. Furthermore, regulatory environments in the Asia Pacific region are generally more conducive to business expansion compared to the more stringent frameworks in North America and Europe. As competition intensifies in mature markets, manufacturers are progressively shifting their focus toward growth opportunities in Asia Pacific and Latin America.

Challenges:
Intracellular cytokine staining (ICS) combined with flow cytometry continues to be the most widely used method for evaluating cytokine co-expression cells, posing a substantial competitive challenge for FluoroSpot assays. Despite FluoroSpot's higher sensitivity, ICS is often preferred due to its reliable performance in fluorescent signal detection-an area where FluoroSpot may encounter difficulties due to signal overlap between different fluorescent dyes. In response to this challenge, companies are investing in advanced detection technologies. For instance, @Mabtech AB has introduced the IRIS analyzer, which incorporates RawSpot technology to improve the accuracy of spot detection.

Regional Trends:
North America is expected to maintain its leadership position in the ELISpot and FluoroSpot assay market over the forecast period. This dominance is largely attributed to the high prevalence of cancer and infectious diseases in the region. According to the American Cancer Society's Cancer Statistics 2022, an estimated 1.92 million new cancer cases were projected in the United States in 2022, including those involving breast cancer, leukemia, and lymphoma. Additionally, a study published by the American Academy of Pediatrics in March 2022 reported that more than one million individuals in the U.S. are living with chronic hepatitis B infections, which can lead to severe conditions such as liver cancer. The growing disease burden is expected to drive increased demand for vaccines and support the widespread adoption of ELISpot assays in infectious disease research.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2000

Recent Developments:
• In Mar 2023, The T-Cell Select reagent kit from Oxford Immunotec, which is designed for in vitro diagnostic (IVD) use by accredited laboratories using the T-SPOT.TB test workflow, has received approval from the U.S. Food and Drug Administration (FDA) for the use of two additional cell isolation tools.
• In Mar 2022, Medix Biochemica launched a new brand to show how its recent acquisitions have made its services more exciting and how committed it is to the in vitro diagnostics (IVD) business. Medix Biochemica became the best IVD raw materials seller because of how quickly it grew.

Segmentation of ELISpot and FluoroSpot Assay Market-
By Product-
• Assay Kits
o Assay Kits by Technique
 ELISpot Assay Kits
 FluroSpot Assay Kits
o Assay Kits by Utility
 Diagnostic Kits
 Research Kits
o Assay Kits by Analyte
 T-cell-based kits
 B-cell-based kits
 Other analytic kits
• Analyzers
• Ancillary products
By Application-
• Diagnostic Applications
o Infectious Diseases
o Transplants
• Research Applications
o Vaccine Development
o Clinical Trials
o Cancer Research
By End-User-
• Hospitals & Clinical Labs
• Research Institutes
• Biopharmaceutical Companies and CROs
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/elispot-and-fluorospot-assay-market/2000

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.